We have received ethics approval for our Phase 2a clinical trial to evaluate the efficacy of our licensed patented cannabinoid formulation in treating patients with chronic pain, receiving ethics approval.
Undertaken in collaboration with La Trobe University’s Sport and Exercise Medicine Research Centre (Melbourne, Australia), a world-leading, randomised, double-blind, placebo-controlled clinical trial that will investigate the efficacy of LEVIN Health’s licensed formula in treating people with chronic pain specifically following musculoskeletal injury. This study is being undertaken with world-renowned sports medicine expert Professor Peter Brukner as Principal Investigator.
With the approval now formally received from the Bellberry Human Research Ethics Committee (HREC), LEVIN Health expects the trial to commence in April 2022, with an expected target of 114 patients enrolled. Interventional Pain Physician, and Chair of the Sports Medicine Australia
Research Foundation, Associate Professor Bruce Mitchell and member of LEVIN Health’s Medical Advisory Board has acknowledged the medical profession’s insistence on robust research.
“I congratulate LEVIN Health and wish them well with the trial. It will provide exactly the robust evidence from a gold-standard study that the Faculty of Pain Medicine of the Australian and New Zealand College of Anaesthetics has called for,” he said.
“La Trobe University is very excited to be investigating the effectiveness of Medicinal Cannabis in treating people with chronic pain following musculoskeletal injury, in a world-first randomised, double blind, placebo controlled clinical trial.“
Professor Peter Brukner – Principle Investigator